Literature DB >> 12753904

Short interfering RNA-directed inhibition of hepatitis B virus replication.

Keisuke Hamasaki1, Kazuhiko Nakao, Kojiro Matsumoto, Tatsuki Ichikawa, Hiroki Ishikawa, Katsumi Eguchi.   

Abstract

RNA interference (RNAi) is the process by which double-stranded RNA directs sequence-specific degradation of mRNA. In mammalian cells, RNAi can be triggered by 21-nucleotide duplexes of short interfering RNA (siRNA). We examined effects of siRNA on hepatitis B virus (HBV) replication. Human hepatoma cells were transfected with HBV DNA and siRNA against HBV-pregenome RNA. Transfection experiments demonstrated that the siRNA reduced the amount of HBV-pregenome RNA and resulted in reduction of the levels of replicative intermediates and viral protein. Our results indicate that siRNA-mediated gene silencing inhibits HBV replication through suppression of viral RNA, which may be useful as a potential therapeutic modality.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12753904     DOI: 10.1016/s0014-5793(03)00400-9

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  47 in total

1.  Quantifying anti-HBV effect of targeted ribonuclease by real-time fluorescent PCR.

Authors:  Jun Liu; Ying-Hui Li; Jin Ding; Wei-Dong Gong; Cai-Fang Xue; Ya Zhao; Yu-Xiao Huang
Journal:  World J Gastroenterol       Date:  2004-10-01       Impact factor: 5.742

Review 2.  Gene therapeutic approaches to inhibit hepatitis B virus replication.

Authors:  Maren Gebbing; Thorsten Bergmann; Eric Schulz; Anja Ehrhardt
Journal:  World J Hepatol       Date:  2015-02-27

3.  Cost-effective method of siRNA preparation and its application to inhibit hepatitis B virus replication in HepG2 cells.

Authors:  Zhi-Kang Qian; Bao-Qin Xuan; Tai-Shan Min; Jian-Feng Xu; Lin Li; Wei-Da Huang
Journal:  World J Gastroenterol       Date:  2005-03-07       Impact factor: 5.742

4.  Two approaches to construct mammalian expression vector of shRNA to reduce expression and replication of HBV in vitro.

Authors:  Hong-Bin Zhang; Jie Wu; Jiang Xian; Lei Pei; Jie Wang
Journal:  Mol Biol Rep       Date:  2007-06-22       Impact factor: 2.316

Review 5.  RNA interference and antiviral therapy.

Authors:  Yan Ma; Chu-Yan Chan; Ming-Liang He
Journal:  World J Gastroenterol       Date:  2007-10-21       Impact factor: 5.742

6.  Genomic analysis of anti-hepatitis B virus (HBV) activity by small interfering RNA and lamivudine in stable HBV-producing cells.

Authors:  Yong Guo; Hongyan Guo; Liang Zhang; Hongying Xie; Xin Zhao; Fangxun Wang; Ze Li; Yahui Wang; Shiliang Ma; Jiaping Tao; Weixing Wang; Yuxiang Zhou; Weiping Yang; Jing Cheng
Journal:  J Virol       Date:  2005-11       Impact factor: 5.103

7.  Decrease of murine cytomegalovirus-induced retinitis by intravenous delivery of immediate early protein-3-specific siRNA.

Authors:  Brendan Marshall; Juan Mo; Jason Covar; Sally S Atherton; Ming Zhang
Journal:  Invest Ophthalmol Vis Sci       Date:  2014-06-06       Impact factor: 4.799

8.  Combination of small interfering RNAs mediates greater inhibition of human hepatitis B virus replication and antigen expression.

Authors:  Zhe Chen; Ze-feng Xu; Jing-jia Ye; Hang-ping Yao; Shu Zheng; Jia-yi Ding
Journal:  J Zhejiang Univ Sci B       Date:  2005-04       Impact factor: 3.066

9.  Progress in the use of RNA interference as a therapy for chronic hepatitis B virus infection.

Authors:  Marc S Weinberg; Patrick Arbuthnot
Journal:  Genome Med       Date:  2010-04-28       Impact factor: 11.117

Review 10.  Harnessing the RNA interference pathway to advance treatment and prevention of hepatocellular carcinoma.

Authors:  Patrick Arbuthnot; Liam-Jed Thompson
Journal:  World J Gastroenterol       Date:  2008-03-21       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.